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OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
transcranial magnetic stimulation (TMS) is an effective therapy in reducing depressive 
symptoms in adults with bipolar depression.  
 
STUDY DESIGN: Systematic review of three randomized controlled trials (RCTs) that were 
published in the English language between 2016 and 2019. 
 
DATA SOURCES: Data sources included articles found using PubMed as the search engine and 
were selected based on their relevance to the research question as well as patient measured 
outcomes.  
 
OUTCOMES MEASURED: Outcomes measured include changes in depression symptoms 
measured using the 17-item Hamilton Depression Rating Scale (HDRS-17) and Modified 24-
item Hamilton Depression Rating Scale (HDRS).  
 
RESULTS: Tavares et al. found that 48% of patients with bipolar depression receiving active 
TMS were treatment responders with a numbers needed to treat (NNT) of 5. Yang et al. showed 
no differences in HDRS scores between groups at baseline and follow-up as shown by p=0.451 
and F-score of 0.577. Finally, Fitzgerald et al. demonstrated a mean change from baseline of 3.4 
in the active group and mean change from baseline of 3.0 in the sham group. While both are 
significant changes, there is no significant change between treatment groups at the conclusion of 
the 4 week study.  
 
CONCLUSIONS: Even though the study by Tavares et al.1 showed a significant improvement 
with TMS in depressive symptoms in adults with bipolar depression, the other two studies by 
Yang et al.2 and Fitzgerald et al.4 demonstrated no difference between treatment groups. Based 
on these conflicting findings, the results from this systematic review are inconclusive. Thus, 
further research is needed that includes sufficiently larger sample sizes and longer treatment 
trials. 
 








Bipolar disorder is a highly disabling affective disorder characterized by mood swings 
and cognitive disturbances with limited therapeutic options.1,2  The average age of onset is 
between 19 and 30 but ranges from 5 to 50 years old, and the prevalence of the disease is equal 
in both males and females.3 Symptoms vary between individuals and type of bipolar disorder, but 
may include persistently elevated mood, irritability, extreme sadness, anxiety, impaired 
judgment, risky behavior, increased libido, racing thoughts, decreased need for sleep, weight 
loss/gain, and fatigue.3 Even though the disorder is characterized by hypomania and mania 
episodes, depressive episodes exceed them in duration and frequency.1 Bipolar depression, the 
depressive aspect of bipolar disorder, is associated with a twenty fold increased risk of suicide, 
and the duration of depressive episodes lasts three to five times as long as a manic or hypomanic 
episode.4 Thus, reducing depressive symptoms in adults with bipolar depression is vital in 
providing these individuals with a better quality of life.  
Bipolar disorder is a prevalent condition with a worldwide prevalence of around 2-3%, 
including both bipolar I and II subtypes.1 During 2010 to 2011 in the United States, 
approximately 46,800 emergency room visits were made each year by persons older than 15 with 
a diagnosis of bipolar disorder, with an overall rate of 3.8 visits per 1,000 persons per year.5 This 
statistic is likely even higher as the onset of bipolar disorder can begin prior to age 15. Since this 
disorder affects a significant amount of the population, it comes with a substantial economic 
cost. The total economic burden of bipolar disorder in the United States was $45 billion over a 
decade ago. Of that total, $7 billion was a result of direct costs of inpatient and outpatient care 
and nontreatment related expenditures, such as costs of criminal justice.6 Individuals with bipolar 
disorder utilize health care services more frequently, and they have visits that are associated with 
much higher medical costs than those without the disorder.  
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The pathophysiology of bipolar disorder is unknown. However, it is known that both 
genetic and environmental factors play a role as it is highly inheritable and often triggered by 
traumatic life events. Because the exact pathophysiology is unknown, the treatment of bipolar 
depression is more complex and difficult than that of unipolar depression. There are limited first-
line therapies for treating bipolar depression, but conventional medical therapies typically 
include selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), atypical 
antipsychotics, anticonvulsants, and mood-stabilizing agents such as lithium. Psychotherapy, 
such as cognitive-behavioral therapy (CBT) and other approaches with a clinical psychologist or 
licensed professional counselor, have shown success in alleviating psychological symptoms. 
Transcranial magnetic stimulation (TMS) is a non-invasive brain stimulation therapy that has 
been proven to be effective in reducing depressive symptoms in those with unipolar depression.1 
It is hypothesized that TMS stimulates neurons in the region of the brain involved in mood 
control and depression. Since TMS has been shown to be effective in unipolar depression and 
there are limited effective first-line therapies for bipolar depression, TMS is being explored as an 
alternative treatment for bipolar depression because the therapy targets mood control neurons. 
The exploration of TMS as a treatment option is critical to physician assistants and other 
medical providers who assess and treat bipolar disorder. It is imperative that they are aware of all 
treatment options, especially those outside of the standard treatment options and those that are 
noninvasive and well-tolerated, such as TMS. Bipolar disorder looks different for every 
individual; therefore, a provider’s knowledge of available treatment options allows them to 
weigh all risks and benefits and develop the best treatment plan for each individual patient.  
OBJECTIVE  
The objective of this selective EBM review is to determine whether or not transcranial 
magnetic stimulation is an effective therapy in reducing depressive symptoms in adults with 
bipolar depression. 




The studies selected for this EBM review were found using the search engine, PubMed, 
while using specific inclusion and exclusion criteria. All three RCTs were found in peer-
reviewed journals and were published in the English language after 2009. Articles were selected 
based on their clinical relevance to the research question and whether or not they included 
patient oriented evidence that matters (POEM). The studies included three randomized controlled 
trials (RCTs) that reviewed adults over 18 years old diagnosed with bipolar disorder who were 
undergoing alternative treatment for their depressive symptoms. The intervention being observed 
in each of the three studies was TMS: Tavares et al.1 used fifty five 18 hertz (Hz) trains delivered 
at 120% of the motor threshold (MT) intensity at 20 second intervals, Yang et al.2 used fifty five 
10 Hz trains delivered at 110% of the MT intensity at 30 second intervals, and Fitzgerald et al.4 
used twenty 10 Hz trains delivered at 110% of the MT intensity at 25 second intervals. All 
studies were compared to a sham transcranial magnetic stimulation that used sham coils that 
mimicked scalp sensations and the acoustic artifact of the active stimulation but without the 
neuronal activation. Outcomes measured in these studies included efficacy in reducing 
depressive symptoms in patients with bipolar depression measured using the 17-item Hamilton 
Depression Rating Scale (HDRS-17) and Modified 24-item Hamilton Depression Rating Scale 
(HDRS). All studies had patients rate their depression symptoms using these scales.  
As stated above, specific inclusion and exclusion criteria were applied to all three 
articles. Inclusion criteria were randomized controlled trials that were published in English 
within the last 10 years and included adults 18 years and older. Exclusion criteria included no 
systematic reviews, articles published prior to 2009, or subjects less than 18 years old. Table 1 
demonstrates all specific inclusion and exclusion criteria for each study analyzed in this review. 
Statistics reported for reduction in depressive symptoms included the following: Control Event 
Rate (CER), Experimental Event Rate (EER), Relative Benefit Increase (RBI), Absolute Benefit 
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Increase (ABI), Numbers Needed to Treat (NNT), F-score (F), p-value, and mean change from 
baseline. 
Table 1. Demographics & Characteristics of Included Studies 
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Outcomes measured in all three studies included changes in depression symptoms 
measured using the 17-item Hamilton Depression Rating Scale (HDRS-17) and Modified 24-
item Hamilton Depression Rating Scale (HDRS), which are two different versions of the same 
scale. All studies had patients answer the questions provided in these scales, and their answers 
were used to assess the severity of their depression and their progression throughout treatment. 
Scoring is based on a 17-item scale and scores of 0-7 are considered normal, 8-16 suggest mild 
depression, 17-23 suggest moderate depression, and scores over 24 indicate severe depression. 
RESULTS 
 Tavares et al.1 conducted a double-blind RCT to study the efficacy and safety of TMS in 
the treatment of bipolar depression patients. Their study involved 50 participants from the 
Clinics Hospital of the University of Sao Paulo ages 18 to 65 years old diagnosed with bipolar 
disorder types I or II according to the DSM-IV criteria, who were in an acute depressive episode 
with an HDRS-17 score of 17 or greater. The subjects needed to be free of any antidepressant 
drugs; however, they were allowed to be on low dose benzodiazepine, lithium, anticonvulsants or 
antipsychotic therapy. The subjects were stimulated on the left dorsolateral prefrontal cortex 
(DLPFC) every day for 4 weeks, except weekends, and they were clinically assessed every week 
using the HDRS-17 scale for a total of 8 weeks to include both the active phase and follow-up 
phase.1 Therefore, their response to the treatment was determined using the HDRS-17 scale, 
looking for a 50% improvement from their baseline. In the experimental group receiving active 
TMS, the experimental event rate was 48% after 4 weeks of treatment, meaning they were 
considered responders to therapy.1 Meanwhile, 24% were considered responders in the control 
group receiving sham TMS.1 Their response to treatment proved TMS to be an effective therapy 
in reducing depressive symptoms when compared to the control group; however, these results 
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were not sustained after the group was re-assessed at week 8, which was 4 weeks after the 
discontinuation of TMS. The NNT in this study was 5; therefore, for every 5 patients, 1 more 
will benefit from treatment. These results are organized in Table 2.  
Table 2. Treatment Responders Using HDRS-17 Scores  
CER EER RBI ABI NNT 
24% 48% 100% 24% 5 
CER: Control Event Rate; EER: Experimental Event Rate; RBI: Relative Benefit Increase; ABI: Absolute Benefit Increase; NNT: Numbers Needed to Treat 
Out of the 50 participants who entered the study, 43 finished the trial. There were two 
drop outs in the sham group due to missing consecutive visits, and there were five drop outs in 
the active group: two were dropped due to missing consecutive visits, two were dropped due to 
the severity of their depressive symptoms, and one was dropped due to the severity of the side 
effects, such as the burning scalp pain.1 Thus, adverse events were considered in this study; 
however, scalp pain was the only event that was determined to be more prevalent in the active 
group compared to the sham group. Additional adverse events were considered, such as 
headache, neck pain, hearing difficulties, and concentration difficulties; however, those who 
experienced side effects were still included in the study.1  
Yang et al.2 conducted a single-blind RCT that included 52 participants ages 18 to 55 
years old diagnosed with bipolar disorder types I or II according to the DSM-IV criteria, who 
were outpatients at the First Hospital of Hebei Medical University and on stable antipsychotic or 
mood stabilizing therapy. The purpose of this study was to determine if TMS was effective and 
safe in improving depressive symptoms and cognitive function in bipolar disorder. The subjects 
were stimulated on the left DLPFC every day for 10 days, and they underwent baseline and 
follow up assessments using the modified 24-item HDRS scale. The data for emotional 
symptoms were analyzed using a 2 x 2 repeated-measures ANOVA, with treatment group (active 
TMS vs sham TMS) as the one factor and time of testing (baseline vs follow-up) as the other 
factor.2 After 10 days of consecutive treatment, there were found to be no differences in HDRS 
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scores between baseline and follow up as demonstrated by an F-score of 0.577 and a p-value of 
0.451.2 Thus, this study failed to prove TMS as an effective therapy for those with bipolar 
depression. These results are displayed in Table 3.  
Table 3. Analysis of HDRS Scores  
Active TMS Sham TMS F-score p-value 
Baseline Follow-up Baseline Follow-up 0.577 0.451 
4.80  2.784 3.20  2.141 4.96  2.919 3.81  2.367 
 
There was no mention of any lost subjects in this study; therefore, without any 
confirmation about losses, it must be assumed that there were losses. Additionally, there were no 
serious adverse events that were reported during or after treatment with TMS, and there were no 
reported drop outs due to side effects. Three participants experienced dizziness during the first 
initial TMS treatment; one receiving active TMS and two receiving sham TMS.2 Thus, dizziness 
was not a noteworthy adverse event related to the active treatment.   
Fitzgerald et al.4 conducted a double-blind RCT to explore the therapeutic benefit of 
TMS in the treatment of bipolar depression. The study included 46 participants ages 18 to 70 
years old diagnosed with bipolar affective disorder in a current episode of treatment resistant 
depression as defined by the DSM-IV criteria, who also have a HDRS-17 score of 20 or greater.4 
The patients needed to be on stable antidepressant or psychoactive drugs without recent increases 
or initiation in the last 4 weeks, and they were all recruited by referral from both community and 
hospital based psychiatrists between January 2009 and May 2015.4 They were stimulated on 
bilateral DLPFC, instead of a unilateral approach, every day between Monday and Friday over 4 
weeks, and they were assessed using the HDRS-17 scale after two and four weeks of treatment. 
The results of the HDRS-17 scores were analyzed using a mean change from baseline 
calculation. At the beginning of the study, the mean baseline HDRS-17 score was 23.2 in the 
active group and 23.0 in the control group.4 At the end of the 4 week study, the mean scores did 
  Boylan, TMS for Bipolar Depression,  
 
8 
improve to 19.8 in the active group and 20.0 in the control group, creating a mean change from 
baseline of 3.4 and 3.0 respectively.4 While there were significant reductions in the HDRS-17 
scores, there was no difference between the treatment groups. See Table 3. 
Table 4. Efficacy of TMS as Measured by Mean Change from Baseline  
 Active TMS Sham TMS 
Baseline  23.2 23.0 
End of Treatment (Week 4) 19.8 20.0 
Mean Change from Baseline 3.4 3.0 
  
There were six identifiable losses in this study. Of the 46 participants, four withdrew 
from the active group and two withdrew from the sham group. Of the four from the active group 
who withdrew, two were due to practical difficulties with attendance, one was due to withdrawn 
consent, and one was due to desire to access alternative treatment. Of the two from the sham 
group who withdrew, one was due to practical difficulties with attendance and the other was due 
to desire to access alternative treatment.4 There were no comments about adverse events and data 
on safety was not reported in this study.  
DISCUSSION 
 Despite all three RCTs having investigated TMS as an effective therapy in reducing 
depressive symptoms in bipolar depression, only one of the articles produced significant data to 
suggest it to be an effective therapy. Tavares et al.1 was likely more successful since it followed 
the methods utilized by a notable study that used TMS for treatment of unipolar depression 
published by Levkovitz in 2015, including stimulation of the left DLPFC and an adequate trial of 
TMS of four weeks. While Tavares et al.1 still showed significant improvement in depressive 
symptoms with four weeks of stimulation, it did not show a sustained response and remission at 
week 8. Thus, the study may have seen more substantial results if the duration of treatment was 
similar to Levkovitz’s study of unipolar depression, where the brain was stimulated for 12 
weeks.  
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 Just as Tavares et al.1 was limited by sample size and duration of treatment, the two 
studies that failed to produce significant data, Yang et al.2 and Fitzgerald et al.4, were also 
limited by those same two factors. None of the studies included more than 52 participants and 
none exceeded active treatment greater than four weeks. While Yang et al.2 included the largest 
sample size (n=52) of the three studies, the study was limited by the duration of treatment, which 
was only 10 days of consecutive treatment. Even though treatment sessions vary in length, a 
typical course is four to six weeks.7 Thus, this study falls significantly short of an adequate trial 
of TMS.  
 Fitzgerald et al.4 also conducted their study over the course of four weeks; however, it 
included the smallest sample size (n=46) of the three studies, causing a lack of sufficient power 
to demonstrate advantage over the sham stimulation.4 Once this study was complete, Fitzgerald 
et al.4 had calculated a sample size that would have demonstrated a significant effect on the mean 
change in HDRS-17 scores, and it would require 157 participants in both the active and sham 
groups.4 This suggests that an adequate sample size was not used for the study, and also suggests 
that it was not used in any of the three studies. Additionally, Fitzgerald et al.4 stimulated both the 
left and right DLPFC. The study may have shown more significant results if it focused on 
stimulating just one side, specifically the left side which shows improvement with TMS in 
unilateral depression.   
 All three of the studies were conducted while the patients were on concurrent drug 
therapy, whether that was mood stabilizing drugs, anticonvulsants, or antidepressant drugs. 
These drugs could be confounding variables; thus, significantly impacting the results of these 
studies as TMS was not being assessed as monotherapy. The brain was already being altered by 
the effect of these drugs; therefore, the true effects of TMS could not be assessed.  
Besides the limitations of the primary research, there were limitations specific to this 
systematic review. There are few existing articles from peer-reviewed journals that focus on 
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TMS as an intervention in reducing depressive symptoms in bipolar disorder; therefore, the pool 
of studies to analyze for this review was limited. The limitation in number made researching the 
intervention in question difficult, so three of the few articles that could be found were analyzed. 
Due to the small number of studies, the quality of the ones selected could be questioned. 
Additional studies need to be performed to further analyze the intervention for this specific 
patient population and provide a larger pool of quality studies.  
Even though there is conflicting data to support TMS in this systematic review, additional 
research needs to be conducted since this noninvasive procedure is efficacious in previous 
unilateral depression studies. Additionally, TMS is widely available in many clinics and 
hospitals across the country.7 The availability makes it a readily accessible treatment option once 
the proper research is conducted to support it as a regular treatment option. TMS is covered by 
most major commercial companies, such as United Healthcare, Cigna, Aetna, and BCBS.8 
However, in order to qualify for insurance coverage, a patient must be diagnosed with major 
depressive disorder, must have tried at least two to four different antidepressants without 
improvement, and/or must have tried psychotherapy without improvement.8 Since it is generally 
well-tolerated, safe, and typically covered by insurance, providers, such as doctors, physician 
assistants, nurse practitioners, and more, should stay informed about the results of further studies 
using TMS as a therapy in reducing depressive symptoms in adults with bipolar depression.  
CONCLUSION 
 Even though one RCT found TMS to be an effective therapy in reducing depressive 
symptoms in adults with bipolar depression, two RCTs did not produce any significant data to 
suggest it to be an effective therapy. Thus, this systematic review produces conflicting evidence 
to determine if TMS is an effective therapy in reducing depressive symptoms in adults with 
bipolar depression. According to this review, it cannot be determined if TMS is an effective 
therapy. This could be due to the methods used in each of the three studies, including sample 
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size, length of treatment, location of stimulation, and concurrent drug therapy use. All three of 
the RCTs are limited by sample size and treatment duration as they all consisted of less than 55 
participants and none lasted longer than four weeks. Thus, TMS cannot be ruled out as an 
effective treatment option for bipolar depression. Further research is warranted that includes 
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